Creative Medical Technology Holdings Expands Neurological Application of ImmCelz® into Parkinson's Disease

Rhea-AI Summary

Creative Medical Technology Holdings (CELZ) announced promising preclinical data suggesting ImmCelz® could treat Parkinson's Disease. Using the MPTP mouse model, ImmCelz® inhibited Parkinsonism-like behavior and protected dopamine cells, enhancing interleukin-10 levels. With over 1 million Parkinson's patients in the USA, this innovation represents a significant market opportunity. The company aims to advance its lead indication, stroke, and address FDA comments before initiating human trials. Overall, this expansion could bolster CELZ's product pipeline in regenerative immunotherapy.

Positive

• Preclinical data indicates ImmCelz® may effectively treat Parkinson's Disease.
• ImmCelz® shows promise in protecting dopaminergic cells and enhancing interleukin-10 levels.
• Significant market potential with over 1 million Parkinson's patients in the USA.
• Advancement of clinical trials for stroke demonstrates commitment to product pipeline growth.

Negative

• None.

PHOENIX, May 24, 2021 /PRNewswire/ -- Creative Medical Technology Holdings, trading under ticker symbol CELZ, announced today positive preclinical data supporting extension of ImmCelz® applicability to Parkinson's Disease.  Using the well established MPTP mouse model of the disease, it was demonstrated that administration of ImmCelz® inhibited onset of Parkinsonism-like behavior and resulted in protection of dopaminergic cells.  Importantly, augmentation of brain protective interleukin-10 protein was observed in treated animals. 

The Company is excited to see that the concept of "regenerative immunotherapy" appears to be applicable to numerous indications, especially in the area of neurological diseases.

The ImmCelz® product utilizes the patient's own blood cells that have been "reprogrammed"  by culturing with established universal donor stem cells followed by re-infusion into the patient.  To date preclinical models of liver failure¹, diabetes², stroke³, rheumatoid arthritis⁴, and now Parkinson's have been shown responsive to ImmCelz® therapy.

"According to the Parkinson's Foundation, there are 1 million patients with this condition in the USA, which is more than the combined number of people diagnosed with multiple sclerosis, muscular dystrophy and Amyotrophic Lateral Sclerosis (ALS)⁵." Said Timothy Warbington, President and CEO of Creative Medical Technology Holdings. "We are committed to advancing our lead indication for ImmCelz®, which is stroke, for which we are currently addressing comments provided by the FDA before we can initiate human trials.  Once human trials are cleared for stroke, we anticipate initiating trials in other indications for which we have seen preclinical efficacy, thus creating a significant product pipeline for this first in class approach we term Regenerative Immunology."

About Creative Medical Technology Holdings 
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in regenerative medicine/stem cell technology in the fields of immunotherapy, urology, neurology and orthopedics and is listed on the OTC under the ticker symbol CELZ. For further information about the company, please visit www.creativemedicaltechnology.com.

Forward Looking Statements 
OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.

Timothy Warbington, CEO

Creativemedicaltechnology.com
www.StemSpine.com
www.Caverstem.com
www.Femcelz.com
www.ImmCelz.com
www.OvaStem.com

 

¹ Creative Medical Technology Holdings Announces Reversion of Liver Failure Using ImmCelz® Personalized Cellular Immunotherapy in Preclinical Model (prnewswire.com) 
² Creative Medical Technology Holdings Announces Positive Data and Patent Filing Using ImmCelz® to Treat Type 1 Diabetes | BioSpace 
³ Creative Medical Technology Announces Successful Application of ImmCelz Immunotherapy for Stroke | American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology 
⁴ Creative Medical Technology Holdings Reports Positive Preclinical Data on ImmCelz® Immunotherapy Product in Rheumatoid Arthritis Model | BioSpace 
⁵ Statistics | Parkinson's Foundation

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/creative-medical-technology-holdings-expands-neurological-application-of-immcelz-into-parkinsons-disease-301297499.html

SOURCE Creative Medical Technology Holdings, Inc.

FAQ

What are the latest developments for CELZ regarding Parkinson's Disease?

Creative Medical Technology Holdings announced positive preclinical data for ImmCelz® in treating Parkinson's Disease.

When will CELZ initiate human trials for ImmCelz®?

The company aims to address FDA comments before initiating human trials for its lead indication, stroke.

How many patients in the USA are affected by Parkinson's Disease according to CELZ?

There are over 1 million patients with Parkinson's Disease in the USA, as stated by CELZ.

What is the importance of interleukin-10 in the CELZ study?

The study found that ImmCelz® treatment resulted in augmented levels of interleukin-10, which is crucial for neuroprotection.

What is the ticker symbol for Creative Medical Technology Holdings?

The ticker symbol for Creative Medical Technology Holdings is CELZ.